By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Depomed, Inc. 

7999 Gateway Boulevard
Suite 300
Newark  California  94560  U.S.A.
Phone: 510-744-8000 Fax: 510-744-8001


Depomed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. The company was founded in 1995 and has established itself by developing and incorporating promising technology into differentiated therapeutic products, taking those products through clinical approval, and building a strong market presence. The company currently markets four FDA-approved products, Gralise® (gabapentin) tablets for the management of Postherpetic Neuralgia (PHN), Cambia® (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older, Zipsor® (diclofenac potassium) liquid filled capsules for relief of mild to moderate acute pain, and Lazanda® (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients.

Depomed also has successfully developed and licensed its unique drug-delivery technology, Acuform®. This patented oral-delivery technology allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. The company’s Acuform technology is currently being used in four marketed drugs, including Gralise.

The Company has successfully executed on strategy and has grown product revenue significantly over the past three years. Located in Newark, CA, Depomed is NASDAQ-listed (DEPO) and currently employs approximately 325 people, of which approximately 250 are within the Commercial organization.

On January 15, 2015, Depomed announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), severe enough to require daily, around-the-clock, long-term opioid treatment, and NUCYNTA® (tapentadol), an immediate release version of tapentadol, for management of moderate to severe acute pain in adults. NUCYNTA (tapentadol) oral solution is an approved oral form of tapentadol that has not been launched. The deal will make NUCYNTA the flagship asset in Depomed's growing portfolio of pain and neurology specialty pharmaceuticals, and is expected to close in 2Q15.

Key Statistics

Ownership: Public

Web Site: Depomed
Symbol: DEPO


Drug Delivery

Company News
Depomed (DEPO)'s Expanded Portfolio Of Pain Management Products Led By The NUCYNTA Franchise To Be Highlighted At PAINWeek 2015 9/2/2015 10:15:24 AM
Horizon Pharma (HZNP) To Amend Preliminary Solicitation Statement To Include Proposed Nominees For Depomed (DEPO)'s Board 8/20/2015 9:27:54 AM
Depomed (DEPO)'s Board Of Directors Unanimously Rejects Revised Proposal From Horizon Pharma (HZNP) 8/20/2015 6:58:39 AM
Horizon Pharma (HZNP) Sends Letter To Depomed (DEPO) Board Of Directors 8/14/2015 10:26:59 AM
Depomed (DEPO) Comments On Horizon Pharma (HZNP) Letter 8/14/2015 7:31:16 AM
Depomed (DEPO) Sends Letter To Horizon Pharma (HZNP) 8/7/2015 6:58:58 AM
Horizon Pharma (HZNP) Files Lawsuit, Seeks Change of Depomed (DEPO)’s Board of Directors in Takeover Attempt 8/4/2015 6:36:37 AM
Horizon Pharma (HZNP) Commences Process To Request A Special Meeting Of Depomed (DEPO) Shareholders 8/3/2015 10:29:14 AM
Depomed (DEPO) Comments On Horizon Pharma (HZNP) Announcement 8/3/2015 10:15:09 AM
Depomed (DEPO) Reports Record Sales And Cash Flow In Second Quarter 2015 And Raises Full Year 2015 Guidance 7/30/2015 1:01:53 PM